(NASDAQ: IRD) Opus Genetics's forecast annual revenue growth rate of 26.53% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 114.69%, and while it is forecast to beat the US market's average forecast revenue growth rate of 23.4%.
Opus Genetics's revenue in 2026 is $14,633,000.On average, 11 Wall Street analysts forecast IRD's revenue for 2026 to be $1,245,976,346, with the lowest IRD revenue forecast at $675,849,238, and the highest IRD revenue forecast at $2,172,372,552. On average, 11 Wall Street analysts forecast IRD's revenue for 2027 to be $1,429,903,889, with the lowest IRD revenue forecast at $675,849,238, and the highest IRD revenue forecast at $3,106,975,499.
In 2028, IRD is forecast to generate $2,201,958,197 in revenue, with the lowest revenue forecast at $743,434,162 and the highest revenue forecast at $4,495,914,648.